Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-03-22

Clinical Trial Update: RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers [EARLY_Phase 1]

View source ↗

Summary

Early-phase (Phase 1) trial update evaluating radioiodine (RAI) plus immunotherapy for recurrent/metastatic thyroid cancer; results were posted on 2024-03-22.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RAI Plus Immunotherapy

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Thyroid Cancer | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-03-22